Amira Pharmaceuticals, Inc. announced AM211, Amira’s internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.

More: continued here

This entry was posted on Sunday, January 11th, 2009 at 10:01 am and is filed under Allergies. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.